Cervical Cancer Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cervical cancer surgery encompasses a spectrum of gynaecological oncological procedures for the surgical treatment of cervical carcinoma — the third most common gynaecological cancer globally and a leading cause of cancer death in lower- and middle-income countries where HPV vaccination and cervical screening programmes are limited. Cervical cancer is predominantly caused by persistent infection with high-risk human papillomavirus (HPV) genotypes 16 and 18. Surgery is the primary treatment for early-stage disease (FIGO Stages IA–IIA), while concurrent chemoradiotherapy (CCRT) — platinum-based chemotherapy combined with external beam radiation and intracavitary brachytherapy — is the standard of care for locally advanced disease (Stages IIB–IVA).

The principal surgical procedure is radical hysterectomy (Wertheim's hysterectomy) — en bloc resection of the uterus, cervix, upper vagina, bilateral parametria, and pelvic lymph nodes — which achieves cure in approximately 85–90% of Stage IB1 and IB2 cervical cancers. The procedure can be performed via open laparotomy, laparoscopic, or robotic-assisted approaches. The LACC (Laparoscopic Approach to Cervical Cancer) randomised trial published in 2018 demonstrated significantly inferior disease-free survival for minimally invasive (laparoscopic and robotic) radical hysterectomy compared to open radical hysterectomy, a landmark finding that has shifted most expert centres back to open or carefully selected minimally invasive approaches with modified protective techniques.

Treatment planning requires a multidisciplinary tumour board review incorporating FIGO clinical staging, MRI pelvis for local extent, PET-CT for lymph node and distant metastasis assessment, histological subtype and grade, and the patient's reproductive wishes. Sentinel lymph node biopsy is increasingly incorporated to accurately stage pelvic lymph node status with reduced morbidity versus full lymphadenectomy.

Primary cervical carcinoma — including squamous cell carcinoma (approximately 70%), adenocarcinoma (25%), and other histological types — is the principal indication for cervical cancer surgery. FIGO Stage IA1 (microinvasive, invasion depth below 3 mm) is treated by conservative excision — large loop excision of the transformation zone (LLETZ/LEEP) or cold knife cone biopsy — which is curative and preserves fertility. Stage IA2 (invasion 3–5 mm) and Stage IB1 (tumour below 4 cm confined to cervix) are treated by radical hysterectomy (Type II/III) with pelvic lymphadenectomy, or concurrent CCRT, with equivalent cure rates. Stage IB2 (tumour above 4 cm, confined to cervix) may be treated by radical hysterectomy, primary CCRT, or neoadjuvant chemotherapy followed by surgery at selected centres.

Persistent or recurrent cervical cancer after primary CCRT is a challenging situation: pelvic exenteration — en bloc resection of the uterus, bladder, and/or rectum with urinary and/or bowel diversion — is the only potentially curative surgical option for central pelvic recurrence, and is performed at specialist centres with five-year survival rates of 25–50% in carefully selected patients. Cervical cancer in pregnancy requires a multidisciplinary approach balancing oncological treatment timing against fetal viability.

Candidates for radical hysterectomy are patients with FIGO Stage IA2 to IB2 cervical cancer who are medically fit for major pelvic surgery, have disease confirmed by examination and MRI to be confined to the cervix and proximal parametria without bladder, rectal, or sidewall involvement, and have no radiological evidence of pelvic lymph node metastasis (though lymphadenectomy is performed as part of the procedure for pathological staging). A pre-operative assessment including full blood count, renal and liver function, chest CT, and anaesthetic assessment is standard. Patients with FIGO IB3 (tumour above 4 cm) or IIA2 (upper vagina involvement) may be treated with primary CCRT or after neoadjuvant chemotherapy, depending on institutional practice and multidisciplinary tumour board decision.

Contraindications to radical hysterectomy include clinical or radiological evidence of parametrial infiltration (converting staging to IIB — better served by CCRT), pelvic sidewall or pelvic lymph node involvement, distant metastasis, severe obesity (BMI above 40 increases surgical and anaesthetic risk substantially), severe pelvic adhesions from prior surgery or endometriosis that preclude safe dissection, and patient preference for non-surgical treatment after informed discussion. Fertility-sparing surgery (radical trachelectomy) is an option for carefully selected young women with Stage IA2–IB1 tumours below 2 cm with no lymphovascular space invasion and no lymph node involvement.

Open radical hysterectomy — the Querleu-Morrow Type B/C classification — remains the gold standard following the LACC trial, which demonstrated superior disease-free and overall survival for open versus minimally invasive radical hysterectomy. The open approach provides tactile feedback, allows wider parametrial resection, and eliminates the uterine manipulator (implicated in tumour dissemination during minimally invasive surgery). Recent studies using modified laparoscopic techniques with a vaginal closure at the start (preventing tumour spillage) suggest outcomes comparable to open surgery in experienced centres, but this remains investigational.

Radical trachelectomy — removal of the cervix and upper vagina with parametria while conserving the uterine corpus — allows subsequent pregnancy in young women with favourable early-stage tumours (below 2 cm, no LVSI, no lymph node involvement). Vaginal radical trachelectomy (Dargent's technique) or abdominal radical trachelectomy preserves reproductive potential with a live birth rate of approximately 60–70% in subsequent planned pregnancies, with recurrence rates comparable to radical hysterectomy in appropriately selected patients. Pelvic and para-aortic lymphadenectomy is performed concurrently via laparoscopy or open surgery. Sentinel lymph node mapping with indocyanine green (ICG) fluorescence or technetium-99 blue dye allows targeted removal of the sentinel node(s) with pathological ultrastaging, reducing the morbidity of full pelvic lymphadenectomy. The LACC trial (2018) established open radical hysterectomy as superior to laparoscopic/robotic approaches for disease-free survival in early cervical cancer, shifting practice back towards open surgery. Sentinel node mapping with indocyanine green fluorescence identifies sentinel node(s) with pathological ultrastaging, reducing the morbidity of full pelvic lymphadenectomy.

Radical hysterectomy for early-stage cervical cancer provides excellent cure rates. Five-year overall survival for FIGO Stage IB1 disease treated by radical hysterectomy is approximately 90–95% at experienced oncological centres. Stage IB2 disease achieves approximately 75–85% five-year survival. Pathological staging of the resected specimen identifies high-risk features — positive lymph nodes, positive surgical margins, parametrial involvement — that mandate adjuvant concurrent CCRT (post-operative 'adjuvant chemoradiation'), further reducing recurrence risk. Surgical staging avoids the toxicity of prophylactic radiotherapy in patients with node-negative disease.

Fertility-preserving radical trachelectomy achieves oncological outcomes comparable to radical hysterectomy in carefully selected patients with Stage IA2–IB1 tumours below 2 cm — a life-changing benefit for young women who wish to retain their reproductive capacity. Live birth rates after trachelectomy are approximately 50–70% in series with structured fertility follow-up, though obstetric risks (preterm delivery, second trimester loss) are higher than in the general population due to cervical insufficiency. Sentinel node biopsy reduces lymphoedema — a significant long-term morbidity of full pelvic lymphadenectomy — from approximately 15–25% with full dissection to below 5% with sentinel node only.

Radical hysterectomy carries specific operative risks related to the extensive pelvic dissection. Ureteric injury — inadvertent transection or devascularisation of one or both ureters during parametrial dissection — occurs in 1–3% of cases and requires immediate surgical repair or stenting. Bladder dysfunction — hypotonic or acontractile neurogenic bladder from disruption of the pelvic autonomic nerves — is the most common long-term functional complication, affecting 15–30% of patients and manifesting as urinary retention requiring clean intermittent self-catheterisation for weeks to months. Nerve-sparing radical hysterectomy techniques preserve the pelvic autonomic nerves and significantly reduce bladder dysfunction rates to 5–10%.

Lymphoedema — chronic lymphatic swelling of one or both lower extremities from pelvic lymphadenectomy — affects 15–25% of patients and can be functionally disabling, requiring lifelong compressive garments and physiotherapy. Pelvic adhesions and small bowel obstruction are recognised long-term complications of any major pelvic surgery. In patients receiving adjuvant post-operative radiation, late radiation toxicity — radiation proctitis, radiation cystitis, vaginal stenosis, and second primary malignancy — adds to the long-term morbidity burden. Intraoperative blood loss, deep vein thrombosis, pulmonary embolism, and wound complications each occur in 2–5% of patients.

After radical hysterectomy, the average hospital stay is five to seven days. Urinary catheter drainage is maintained for seven to fourteen days to allow bladder recovery; all patients are taught clean intermittent self-catheterisation before discharge in case of persistent urinary retention. Physiotherapy with graduated mobilisation commences on day one post-surgery. Adjuvant concurrent CCRT — indicated for pathologically node-positive disease, positive margins, or parametrial involvement — begins four to six weeks after surgery.

Surveillance follows a structured schedule: clinical examination, vault smear, and clinical review every three months for the first two years, then every six months for years three to five, and annually thereafter. CT or PET-CT imaging is performed at suspicious clinical findings. CA-125 is not a marker for cervical cancer; vault vault Pap smears detect local recurrence at the vaginal cuff. Sexual rehabilitation — using vaginal dilators and oestrogen cream for menopausal patients if oophorectomy was performed — is important for long-term sexual and pelvic floor function. Women who retain their ovaries (standard for Stage I disease below age 45) are not rendered immediately menopausal by radical hysterectomy.

Radical hysterectomy for cervical cancer in the United States costs USD 25,000–60,000 including surgeon fees, anaesthesia, hospitalisation, and pathological staging; costs rise significantly if adjuvant chemoradiotherapy is required. UK NHS provides treatment through cancer pathways without direct patient cost. In India — a country with a high burden of cervical cancer and highly experienced gynaecological oncology centres — radical hysterectomy with lymphadenectomy at Tata Memorial Hospital (Mumbai), Apollo Hospitals, or AIIMS costs USD 4,000–10,000 total, including staging workup, surgery, and hospitalisation. Indian gynaecological oncologists trained at internationally recognised programmes perform Wertheim's hysterectomy with nerve-sparing techniques at these centres.

Thailand (Bangkok Hospital, BNH Hospital) charges USD 8,000–18,000; Turkey (Acibadem, Medicana) USD 6,000–14,000; Malaysia (Pantai, Gleneagles) USD 7,000–15,000. Medical tourism for cervical cancer surgery is established among patients from sub-Saharan Africa, the Middle East, and Southeast Asia, drawn by the affordability and quality of Indian gynaecological oncology centres. The multidisciplinary tumour board must review the case before any surgical plan is finalised, and patients should ensure the destination centre has formal gynaecological oncology subspecialty certification and access to adjuvant CCRT if pathological staging results require it.

Concurrent chemoradiotherapy (CCRT) — weekly platinum chemotherapy combined with external beam pelvic radiotherapy and intracavitary brachytherapy — is the standard of care for FIGO Stage IIB and above disease, and is an alternative to surgery for Stage IB1–IB2 disease with equivalent survival outcomes in randomised comparisons. CCRT avoids surgical morbidity but introduces radiation toxicity (proctitis, cystitis, vaginal stenosis) and renders patients infertile if intracavitary brachytherapy is delivered, which may be preferable for patients who are poor surgical candidates or prefer non-surgical management. For Stage IA1 disease, large loop excision of the transformation zone (LLETZ) alone is curative with a positive margin rate of below 5% and preserves fertility completely. Neoadjuvant chemotherapy (NACT) followed by surgery for IB2–IIA disease is practised at some centres, particularly in resource-limited settings where radiotherapy infrastructure is unavailable, though evidence of superiority over CCRT or primary surgery is inconsistent.